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Introduction
Bluetongue virus (BTV) first emerged in the European
Union (EU) in 2006, peaking at 45,000 cases in 2008.
The EU spent million of euros in 2008 and 2009 on era-
dicating and monitoring programs, co-financed with
member states. The number of cases in 2009 was 1118,
with only 120 reported across the EU so far last year.
Vaccination has proven itself as the most effective tool
to control and prevent the disease and to facilitate the
safe trade of live animals.
Mammalian cells are commonly used as a substrate
for production of most of the viral vaccines. BHK-21
cells are used for the production of bluetongue vaccines.
Most companies use roller bottles or conventional bior-
eactors, but taking into account that the manufacturing
cost is very important, the possibility of using Single-
Use Bioreactor (SUB) technology as an alternative to
roller bottles or conventional bioreactors was explored.
Advantages like yields of production, time reduction
(elimination of cleaning and sterilization steps needed
for bioreactors, no validation process, etc) and quality of
antigen production were studied.
Materials and methods
Cell line
BHK-21 cell line was used due to the good yields. Cells
were cultured at 37°C in Minimum Essential Medium
Glasgow supplemented with serum.
Cultivation system
The growth of the BHK-21 cells and virus production
was conducted in roller bottles (RB), 10-L bioreactor
(Biostat B-plus) and in 250-L SUB (Hyclone).
Cells on bioreactors and SUB were cultivated using
microcarriers (Cytodex-3) at a density of 3g/L. The crys-
tal violet dye nucleus staining method was used to esti-
mate cell density.
Dissolved oxygen (DO) and pH were automatically
adjusted by addition gases (CO2, and air).
Virus strain
BTV serotype 8 (BTV-8), strain BEL2006/02 was used in
all experiments. The strain was supplied by “Veterinary
and Agrochemical Research Centre” (VAR-CODA-
CERVA), Ukkel, Belgium.
Once the cells were 80-100% confluent, RB, 10-L bior-
eactor and 250-L SUB were infected under identical
conditions and with a constant multiplicity of infection
(MOI). Harvesting of virus was done when cytopathic
effect (CPE) was about 90- 100%.
Virus production was evaluated by TCID50/ml.
Vaccine
The antigen obtained on SUB was inactivated by Binary
Ethylenimine (BEI) and adjuvanted with aluminum
hydroxide and saponin. The efficacy of the vaccine was
tested in lambs.
Animals and experimental design
Forty, 1.5 month-old, lambs were included in the study.
Thirty lambs were vaccinated and revaccinated 3
weeks later by subcutaneous route and ten lambs were
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revaccination all lambs were challenged with BTV-8.
The antibody response in vaccinated lambs was evalu-
ated from vaccination until the moment of challenge by
a seroneutralization test (see table 1).
Viremia (presence of BTV genome in blood samples)
was evaluated by real time qRT-PCR [1] in blood sam-
ples obtained before challenge and during four weeks
after challenge.
Results and discussion
Some experiments to scale-up were done. An optimized
and transferable process was developed in 10L glass ves-
sels by monitoring the pH, temperature, and DO. The
final process was transferred to 250-L stirred-tank SUB
integrated with an Applikon controller.
Cell growth and virus production in SUB was con-
ducted at the optimal conditions determined previously
on conventional bioreactors. Three critical parameters
were taken into account: Cell concentration, growth rate
at start virus inoculation and harvesting time.
Cell growth
Several studies were conducted to compare the growth
of cells in RB, 10-L bioreactor and 250-L SUB. During
culture in bioreactors and SUB, DO was regulated by
pulse of oxygen and pH was controlled.
Figure 2, shows that cell concentration at 48 hours
(when confluency is reached) was higher in bioreactors
than in roller bottles. That corresponds to an increase
of cell biomass by a factor of 1.5.
Virus production
Figure 3, shows the results of the virus titers in 250-L
SUB compared with those obtained in RB and 10-L
bioreactor.
The virus titer reached in a 10L bioreactor was com-
parable with the levels obtained in SUB. Preliminary
results prove that by using SUB, the yields obtained in
roller bottles can increase more than two times.
Efficacy study
The potency of antigens produced using 250-L SUB
technology was verified in target species.
Serological study
Determination of neutralizing antibodies (NA) titer
against BTV serotype 8 in the samples taken after vacci-
nation and revaccination was done by means of sero-
neutralization test. Table 1 show the geometric mean
NA titers.
Evaluation of viremia after challenge
I na n yo ft h el a m b so ft h ev a ccinated and challenged
groups, viral gemone could be detected by RT-PCR dur-
ing 27 days after challenge. Whereas in all unvaccinated
and challenged lambs, the viral genome was detected
from day 3-5 p.i.
Conclusions
￿ The results obtained using a 250-L SUB concerning
the cell concentration and virus titer, were similar to
those reached in a 10L bioreactor and higher than in
roller bottles.
Table 1 NA titers against BTV serotype 8 after
vaccination
Mean NA Titers
Group D<0 D+35 D+42 D+65
vaccinated <2 88,4 34,7 50,5
unvaccinated <2 <2 <2 <2
D<0:before first vaccination
D+35: 2 weeks after revaccination
D+42: 3 weeks after revaccination
D+65:before the challenge
Figure 1 Scale-up from roller bottles to 250-L SUB
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antigen produced in SUB are similar of the antigen pro-
duced both in roller bottles and on conventional
bioreactor.
￿ We can think on the possibility of using disposable
systems in vaccines production in order to reduce the
production costs.
￿ SUB can be an alternative to conventional produc-
tion methods:
⠼ Reduced facility complexity, reduction of the cost
of building, and possibility of the rapid expansion of the
capacity of the production.
⠼ Reduction of the capital of equipment and equip-
ment validation, etc.
⠼ Avoid the cleaning process and reduction of the
risk of cross-contamination.
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Figure 2 BHK-21 concentration at 48 hours post cultivation.
Figure 3 Virus titers obtained at 72h p.i.
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